As one of the current most popular immunotherapies, CAR-T therapy shows its strength by boosting the patients’ own immune system to destroy cancer. Creative Biolabs has accumulated extensive experience in the discovery and development of optimized CAR-T therapies. Leverage the expertise of our experienced scientists to expedite and innovate your therapeutic CAR-T projects, we are inspired by NR4A target and are dedicated to providing NR4A knock out CAR-T cell development services.
Recently, NR4A was identified as a key mediator of T cell dysfunction through genomic analysis, and also, NR4A transcription factors play the inhibitory role in CAR-T cell function in solid tumors. These two studies indicate that NR4A may be one of the potential targets to improve the CAR-T efficacy in solid tumors. Chen Dong’s team used an in vitro T cell tolerance induction system to characterize genome-wide epigenetic and gene expression levels in tolerant T cell. Finally, they found that NR4A1 shows high expression levels in tolerant T cells. Moreover, NR4A1 deletion overcomes T cell tolerance and promote effector function, as well as enhancing anti-tumor and chronic virus immunity (see Fig.1 left). As a key regulator in the T cell dysfunction, NR4A1 is a potential target for tumor immunotherapy.
Fig.1 (left) Disruption of NR4A1 prevents T cell exhaustion caused by tumor and viral infection. (Liu, 2019); (right) NR4A-deficient CAR TILs promote tumor regression and prolong survival. (Chen, 2019)
Joyce Chen’s team found that NR4A triple knockout (NR4A1, NR4A2, NR4A3) CAR-T cells promoted tumor killing and improved the survival of tumor-bearing mice (see Fig.1 right). This indicates that NR4A inhibition can be as a promising strategy for cancer immunotherapy.
Over a decade of extensive experience in one-stop CAR-T cell therapy development, Creative Biolabs has established a series of solutions including Biomarker Identification & Selection, scFv Generation, CAR Design & Construction, CAR-T Gene Packaging & Delivery, In Vitro Assay Services, Preclinical In Vivo Assays, etc. Recently, our scientists developed cutting-edge CRISPR-Cas9 technology to edit CAR-T cells. Our CRISPR/Cas9 solution will help our clients to develop the highly efficient engineered CAR-T cells with improved anti-tumor efficacy. Based on our one-stop CAR-T cell development services and CRISPR/Cas9 technology, we are dedicated to providing NR4A knock out CAR-T cell development services to advance your CAR-T cell therapy to treat solid tumors.
Earning the Trust of Our Clients Everywhere, Every Day
-Leverage the expertise of our senior scientists to expedite and innovate your CAR-T therapy-
As a leading CAR-T therapy development provider, Creative Biolabs is committed to guiding our clients in an end-to-end manner to ensure the optimal strategy and fit your expected features within budget and timeline. If you are interested in NR4A to knock out CAR-T cell development, please contact us for more information and a detailed quote.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE